Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Neutral 57.4%

Neg 0% Neu 57.4% Pos 0%

Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.